At HOOKIPA, we envision a world in which cancers and infectious diseases can be chronically managed or eradicated. 

HOOKIPA Pharma Inc. (NASDAQ: HOOK) is a clinical-stage biopharmaceutical company advancing the field of immunotherapy through the development of new immunotherapies based on our proprietary arenavirus platform, which is designed to mobilize and amplify targeted T cells and thereby fight or prevent serious disease.

Our pipeline includes wholly owned investigational arenaviral immunotherapies targeting HPV16+ cancers, prostate cancer, KRAS-mutated cancers (including colorectal, pancreatic and lung), and other undisclosed programs. In addition, HOOKIPA aims to develop functional cures for HBV and HIV in collaboration with Gilead.

As a company, we fight for innovation; we challenge ourselves to act authentically and transparently; we thrive on our differences; and we go for it, never giving up in our efforts to eliminate the suffering of people with cancer and infectious disease.

To learn more please visit www.hookipapharma.com. 


Biotechnology

Life Sciences

Pharmaceutical

HOOKIPA Pharma Inc.

HOOKIPA Pharma Inc.'s headquarters in New York, NY, United States

Jessica Alderton

Reinhard Kandera

Roland Bauer

James Lam

Sandra H.

Bernhard Binder

Silvia S.

Claus Osterbauer

Ilian Tchakov

Jan Micksch

Description

People (2)

Siddhi Patel

James Lam

Jobs